Serum β-d-glucan of critically ill patients with suspected ventilator-associated pneumonia: Preliminary observations

Journal of Critical Care

Volumn 26, Issue 5, 2011, Pages 536.e1-536.e9

  Heyland, Daren ^a,b   Jiang, Xuran ^b   Day, Andrew G ^b   Laverdiere, Michel ^c  

^a QUEEN S UNIVERSITY   (Canada)

^b KINGSTON GENERAL HOSPITAL   (Canada)

^c MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

Author keywords

C reactive protein; Candida; Critical care; Interleukin 6; Pneumonia; Procalcitonin; d Glucan

Indexed keywords

BETA 1,3 GLUCAN;

ADULT; AGED; ARTICLE; BACTERIAL GROWTH; BACTERIUM CULTURE; CANDIDA; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DEATH; FEMALE; HOSPITAL ADMISSION; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PROTEIN BLOOD LEVEL; VENTILATOR ASSOCIATED PNEUMONIA;

EID: 80053457454     PISSN: 08839441     EISSN: 15578615     Source Type: Journal    
DOI: 10.1016/j.jcrc.2011.01.002     Document Type: Article

References (29)

1. Safdar N., Dezfulian C., Collard H.R., et al. Clinical and economic consequences of ventilator-associated pneumonia: a systematic review. Crit Care Med 2005, 33(10):2184-2193.
2. Muscedere J., Martin C., Heyland D.K. The impact of ventilator associated pneumonia on the Canadian health care system. J Crit Care 2008, 23:5-10.
3. Muscedere J.G., Shorr A.F., Jiang X., Heyland D.K. Adequacy of empiric antibiotic therapy for ventilator associated pneumonia: Still an important determinant of outcome. Am J Respir Crit Care Med 2010, 18(1):A3239.
4. Muscedere J.G., McColl C., Shorr A., Jiang X., Marshall J., Heyland D.K. Determinants of outcome in patients with a clinical suspicion of ventilator associated pneumonia. J Crit Care 2008, 23:41-49.
5. Rello J., Esandi M.E., Diaz E., Mariscal D., Gallego M., Valles J. The role of Candida sp isolated from bronchoscopic samples in non-neutropenic patients. Chest 1998, 114(1):146-149.
6. Wood G.C., Mueller E.W., Croce M.A., Boucher B.A., Fabian T.C. Candida sp. isolated from bronchoalveolar lavage: clinical significance in critically ill trauma patients. Intensive Care Med 2006, 32(4):599-603.
7. Delisle M.S., Williamson D.R., Perreault M.M., Albert M., Jiang X., Heyland D.K. The clinical significance of Candida colonization of respiratory tract secretions in critically ill patients. J Crit Care 2008, 23(1):11-17.
8. Perreault M.M., Delisle M.S., Williamson D.R., Albert M., Jiang X., Day A.G., et al. Impact of Candida species on clinical outcomes in patients with suspected ventilator-associated pneumonia and negative cultures. Crit Care Med 2008, 36:A115.
9. Williamson D., Heyland D.K., Martin A., Delisle M.S., Perreault M., Day A., et al. Effect of Candida sp. in respiratory tract secretions on systemic inflammation. Crit Care Med 2008, 36:A115.
10. Young S.H., Ostroff G.R., Zeidler-Erdely P.C., Roberts J.R., Antonini J.M., Castranova V. A comparison of the pulmonary inflammatory potential of different components of yeast cell wall. J Toxicol Environ Health A 2007, 70(13):1116-1124.
11. Muller V., Viemann D., Schmidt M., et al. Candida albicans triggers activation of distinct signaling pathways to establish a proinflammatory gene expression program in primary human endothelial cells. J Immunol 2007, 179(12):8435-8445.
12. Inoue K., Takano H., Oda T., et al. Candida soluble cell wall beta-d-glucan induces lung inflammation in mice. Int J Immunopathol Pharmacol 2007, 20(3):499-508.
13. Lebron F., Vassallo R., Puri V., Limper A.H. Pneumocystis carinii cell wall beta-glucans initiate macrophage inflammatory responses through NF-kappaB activation. J Biol Chem 2003, 278(27):25001-25008.
14. Hahn P.Y., Evans S.E., Kottom T.J., Standing J.E., Pagano R.E., Limper A.H. Pneumocystis carinii cell wall beta-glucan induces release of macrophage inflammatory protein-2 from alveolar epithelial cells via a lactosylceramide-mediated mechanism. J Biol Chem 2003, 278(3):2043-2050.
15. McCann F., Carmona E., Puri V., Pagano R.E., Limper A.H. Macrophage internalization of fungal beta-glucans is not necessary for initiation of related inflammatory responses. Infect Immun 2005, 73(10):6340-6349.
16. Odabasi Z., Mattiuzzi G., Estey E., Kantarjian H., Saeki F., Ridge R.J., et al. beta-d-Glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis 2004, 39:199-205.
17. Ostrosky-Zeichner L., Alexander B.D., Kett D.H., Vazquez J., Pappas P.G., Saeki F., et al. Multicenter clinical evaluation of the (1->3) beta-d-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis 2005, 41:654-659.
18. Pazos C., Ponton J., Del Palacio A. Contribution of (1->3)-beta-d-glucan chromogenic assay to diagnosis and therapeutic monitoring of invasive aspergillosis in neutropenic adult patients: a comparison with serial screening for circulating galactomannan. J Clin Microbiol 2005, 43:299-305.
19. Takesue Y., Kakehashi M., Ohge H., Imamura Y., Murakami Y., Sasaki M., et al. Combined assessment of beta-d-glucan and degree of Candida colonization before starting empiric therapy for candidiasis in surgical patients. World J Surg 2004, 28:625-630.
20. Heyland D.K., Govert J., Garrard C. Waveform abnormalities of APTT in critically ill hospitalized patients: the WATTCH study. Crit Care Med 2006, 34(12):A100.
21. Knaus W.A., Draper E.A., Wagner D.P., Zimmerman J.E. APACHE II: a severity of disease classification system. Crit Care Med 1985, 13(10):818-829.
22. Vincent J.L., Moreno R., Takala J., et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 1996, 22(7):707-710.
23. Presterl E., Parschalk B., Bauer E., Lassnigg A., Hajdu S., Graninger W. Invasive fungal infections and (1,3)-B-d-glucan serum concentrations in long-term intensive care patients. Int J Infect Dis 2009, 13:707-712.
24. Leon C., Ruiz-Santana S., Saavedra P., Galvan B., Blanco A., Castro C., et al. Usefulness of the 'Candida score' for discriminating between Candida colonization and invasive candidiasis in non-neutropenic critically ill patients: a prospective multicenter study. Crit Care Med 2009, 37:1624-1633.
25. Digby J., Kalbfleisch J., Glenn A., Larsen A., Browder W., Williams D. Serum glucan levels are not specific for presence of fungal infections in intensive care unit patients. Clin Diagn Lab Immunnol 2003, 10:882-885.
26. Laverdiere M., Labbe A.C., Restieri C., Rotstein C., Heyland D., Madger S., et al. Susceptibility patterns of Candida species recovered from Canadian intensive care units. J Crit Care 2007, 22:245-250.
27. Magill S.S., Swoboda S.M., Johnson E.A., Merz W.G., Pelz R.K., Lipsett P.A., et al. The association between anatomic site of Candida colonization, invasive candidiasis, and mortality in critically ill surgical patients. Diagn Microbiol Infect Dis 2006, 55:293-301.
28. Meersseman W., Lagrou K., Spriet I., Maertens J., Verbeken E., Peetermans W.E., et al. Significance of the isolation of Candida species from airway samples in critically ill patients: a prospective, autopsy study. Intensive Care Med 2009, 35:1526-1531.
29. Takesue Y., Kakehashi M., Ohge H., Imamura Y., Murakami Y., Sasaki M., et al. Combined assessment of β-d-glucan and degree of Candida colonization before starting empiric therapy for candidiasis in surgical patients. World J Surg 2004, 28:625-630.